Obsidian Therapeutics, Inc. OBX
10.74 USD -2.49 (-18.82%)
Nov 4, 2026, 3:26 PM EST
10.69 Day range 13.75
10.69 52-week range 49.97
- YTD
- -38.63%
- 1 year
- -38.63%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 39.00 +263.1% upside
Now 10.74
- Target (low)
- 32.00
- Target (mean)
- 39.00
- Target (high)
- 43.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.44 | -0.47 – -0.41 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Next quarter | -0.555 | -0.61 – -0.50 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Current year | -2.24 | -2.62 – -1.85 | -2,057.27 | +99.9% | 0 | 0.0% | 2 |
| Next year | -2.79 | -3.85 – -2.13 | -2.24 | -24.8% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2026 | Leerink Partners | Initiated | — | Outperform |
| Sep 9, 2026 | William Blair | Initiated | — | Outperform |
| Aug 18, 2026 | LifeSci Capital | Initiated | — | Outperform |
| Aug 5, 2026 | Piper Sandler | Initiated | — | Overweight |